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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A47primary hand OA with mild to moderate pain symptoms. Further
investigation is required to determine the efﬁcacy of HCQ in other hand
OA phenotypes.
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THE EFFECT OF WALKING EXERCISE REGIMENS ON JOINT
BIOMECHANICS AND SERUM BIOMARKER PROFILE IN PATIENTS
WITH KNEE OSTEOARTHRITIS
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Purpose: Although walking exercise is commonly prescribed to
patients with knee osteoarthritis (OA), there is limited evidence
regarding the safe mode and volume of walking exercise beyond which
a patient may be potentiating further joint damage leading to reduced
clinical beneﬁts. The present study is the ﬁrst that aims to determine
the speciﬁc features of a walking exercise program beyond which
accelerated rates of joint damage are expected using both bio-
mechanical and biochemical outcome measures. Objective 1: Deter-
mine the inﬂuence of increasing walking volume as a single continuous
session versus multiple intermittent shorter sessions on knee joint
biomechanics as assessed by the change in the knee contact force (KCF)
proﬁle. Objective 2: Investigate the effect of continuous versus inter-
mittent walking regimen on serum concentration of a biomarker that
has been associated with cartilage turnover (cartilage oligomatrix
protein, COMP).
Methods: Twenty-eight subjects aged >50 with unilateral sympto-
matic knee OA who met the American College of Rheumatology
clinical criteria and a Kellgren-Lawrence radiographic OA grading of
>2 were recruited. All subjects completed two walking exercise ses-
sions separated by at least 72 hours: 1) a single session of 45 minutes
of continuous walking, and 2) three separate 15-minute bouts of
walking with a 1-hour rest period between each bout, for a total of 45
minutes of walking exercise. For both walking sessions, biomechanical
data consisting of passive marker trajectories and ground reaction
force data along with 5-ml blood samples were collected at baseline
and after every 15 minutes of cumulative walking exercise. Passive
marker trajectories and ground reaction force data were used to create
subject speciﬁc, muscle driven, gait simulations using Opensim to
estimate the ﬁrst and second peaks in the KCF while walking on a
treadmill. Additionally, serum concentration of COMP was quantiﬁed
using ELISA. To determine whether KCFs or Serum COMP concen-
trations varied between continuous and intermittent walking con-
ditions, a 2x4 (condition x walking time) factorial analysis of variance
(ANOVA) with repeated measures was performed for each variable of
interest.
Results: A signiﬁcant walking time effect was observed for the ﬁrst peak
in KCF (F3,81¼ 5.52, P ¼ 0.002) but there was no condition effect or a
condition x walking time interaction. When averaged across the two
walking conditions, post-hoc analysis revealed a signiﬁcant increase in
the ﬁrst peak of KCF equivalent to 25% of body weight after 30 minutes
(P¼0.004) and 45 minutes of cumulative walking (P¼0.009). No con-
dition effect, walking time effect, or condition x walking time inter-
action was observed for the second peak in KCF. A signiﬁcant condition
x walking time interaction (F3,81¼3.50, P¼ 0.02) was also observed for
the changes in COMP concentration, but there were no signiﬁcant
condition effect or walking time effect. Continuous walking was asso-
ciated with a signiﬁcant cumulative increase in COMP concentration
from baseline to 45 minutes (23% increase, P < 0.05), whereas, COMP
concentrations dropped to baseline levels after 30 minutes of inter-
mittent walking with rest breaks.
Conclusions: Cumulative increases in walking exercise volume of
greater than 30 minutes (irrespective of walking regimen) were asso-
ciated with an increase in the ﬁrst peak in KCF equivalent to 25% of body
weight, suggesting a signiﬁcant increase in articular cartilage loading
proﬁles that may be undesirable. The continuous walking regimen
appeared to potentiate an increase in serum COMP concentration at 45
minutes, while an intermittent walking regimen that involved rest
breaks did not. Together our preliminary ﬁndings suggest that pre-
scription of walking exercise of greater than 30 minutes may lead to
undesirable joint loading conditions, while addition of rest breaks may
attenuate the potential negative effects of longer bouts of walking
exercise on cartilage health.39
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Purpose: Intra-Articular injections (IA) with hyaluronic acid (HA) are
used for treating symptomatic osteoarthritis (OA), despite divergent
opinions concerning its effectiveness. The aim of this study was to
explore and identify factors from randomized trials (RCTs), which
explain controversies around the potential efﬁcacy of IA HA compared
to IA sham, IA control, or non-intervention control therapies in patients
with symptomatic OA of the knee, hip and other joints.
Methods: A systematic review and stratiﬁed meta-analysis of available
RCTs was conducted. Methods of the analysis and inclusion criteria
were speciﬁed in advance and registered in the International Pro-
spective Register of Systematic Reviews, PROSPERO registration no.
CRD42014007284. MEDLINE, EMBASE, Cochrane Central Register of
Controlled trials (CENTRAL), Web of science and other resources were
searched for trials in any language. The outcome “pain” was assessed
according to a pre-speciﬁed hierarchy of potentially available outcomes.
Reviewers used duplicate abstractions and independently assessed risk
of bias using the risk of bias tool recommended by Cochrane Collabo-
ration. Hedges’s standardized mean difference (SMD [95%CI]) served as
effect size. REstricted Maximum Likelihood (REML) mixed-effects
models were used to combine study results calculating I-squared and
Tau-squared estimates using STATA. To empirically quantify reasons for
the apparent heterogeneity across studies, a number of stratiﬁed
analyses of the primary outcome were performed according to the trial
characteristics.
Results: Ninety-nine trials, including 115 comparisons (14,804
patients), met the inclusion criteria: Of these, 85 comparisons (11,216
patients) had adequate data available for enabling inclusion in the
meta-analysis. Compared with control, HA reduced pain with an effect
size of -0.39 [-0.47 to -0.41; P<0.001]. There was a high level of
inconsistency (I2¼73%). Adjusting for selective outcome reporting in 30
of the comparisons by imputing data from “null ﬁndings” for the studies
that did not report on pain reduced the combined estimate to -0.30
[-0.37 to -0.23; P<0.001]. Three important variables explaining the high
heterogeneity were overall risk of bias, blinding of personnel and trial
size. Overall risk of bias reduced the heterogeneity (according to Tau-
squared) by 26 %, showing an effect size for low risk of bias trials of
-0.00 [-0.13 to 0.12] compared to -0.35 [-0.43 to -0.27] and -0.81 [-1.19
to -0.44] for high and unclear risk of bias, respectively. Furthermore,
blinding of personnel and trial size reduced the heterogeneity by 26%
and 25% respectively (interaction P<0.001).
Conclusions: Based on available trials, IA HA showed statistically sig-
niﬁcant clinical effect. Small-study bias and the risk of selective out-
come reporting, suggest a lower effect size corresponding to a small,
although statistically signiﬁcant, effect. Stratiﬁed analyses showed
three important variables explaining heterogeneity; Overall Risk of Bias,
blinding of personnel and trial size. Trials with low risk of bias did not
seem to be associated with effect.
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DOES PATELLO-FEMORAL BRACE THERAPY REDUCE SYNOVITIS
ASSESSED BY DYNAMIC CONTRAST ENHANCED MRI?
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Purpose: Osteoarthritis (OA) is associated with inﬂammatory changes
within an affected joint including synovitis. We previously demon-
strated that a patellar brace both reduced pain and decreased MRI
bone marrow lesions in patellofemoral joint (PFJ) OA. While static
synovial volume was not affected by this brace, RA studies and our
ﬁndings in a steroid trial (OARSI, 2014) suggest that changes in the
